RevImmune

RevImmune is a biotechnology company headquartered in Hanover, Maryland, in the United States, with a fully operational subsidiary in Paris, France. The company describes its focus as T-cell technology and development, and its principal product is an IL-7 therapy intended to provide global T-cell support for immunotherapies. IL-7 is a cytokine that plays a central role in T-cell development, survival and proliferation, which makes it relevant to cancer immunotherapy and to settings where T-cell reconstitution is needed. The company operates as a transatlantic organisation, combining a US corporate base with a French research and development presence. Its leadership team includes founder Michel Morre, DVM, MSc, who serves as Chief Scientific Officer; Frederique Berbille, MSc, Director of Clinical Operations; Anne Gregoire, MSc, PhD, Director of Process Development; and Kari ne Marie, MSc, Senior Manager of Quality Systems. This mix of scientific, clinical, process-development and quality roles reflects a company focused on advancing a biologic candidate through development and clinical evaluation. RevImmune positions itself within the immuno-oncology and immunotherapy support space, where its IL-7 asset is presented as a way to enhance or restore T-cell function alongside other immunotherapeutic approaches. The company's public communications emphasise collaboration and scientific partnerships, describing its work under the banner of "Top Notch Collaborations." Its website serves as the primary public source of information about its technology and organisation. As a privately held company, RevImmune does not disclose a stock ticker or public listing. Its exact founding year is not stated in the available evidence. The company remains active, with operations spanning the United States and France.

RevImmune is a biotechnology company headquartered in Hanover, Maryland, United States, with a fully operational subsidiary in Paris, France. The company was founded by Michel Morre, DVM, MSc, who serves as its Chief Scientific Officer. The available public evidence does not specify the exact year of incorporation or the full sequence of early corporate events. From its public materials, RevImmune has built its identity around T-cell technology and development. Its principal asset is an IL-7 product, which the company describes as providing global T-cell support for immunotherapies. IL-7 is a cytokine with a well-established role in T-cell biology, and the company's focus places it in the broader immuno-oncology and immunotherapy-support field. The company operates across two countries: a US headquarters in Hanover, Maryland, and a French subsidiary in Paris. This transatlantic structure supports both corporate and scientific activities. Its leadership team combines clinical operations, process development and quality systems expertise, which is consistent with a company advancing a biologic candidate through development stages. RevImmune's public communications highlight collaboration, using the phrase "Top Notch Collaborations" to describe its partnership approach. As a privately held company, it does not have a public listing or ticker. The company remains active as of the available evidence.

Biotechnology company specialising in T-cell technology and development, providing IL-7 as global T-cell support for immunotherapies.

• IL-7

1. 1T-Cell Technology & Development | RevImmune | United Statesrevimmune.com
2. 2About Us | RevImmunerevimmune.com
3. 3RevImmune (United States)wikidata.org